Drug Delivery
EXECUTIVE INTERVIEW – Catalent Applied Drug Delivery Institute: Helping to Get Better Drugs to Waiting Patients, Encouraging the Adoption of Advanced Delivery Technologies
Drug Development Executive: Kurt Nielsen, PhD, CTO & SVP, Innovation & Growth, and Founding Institute Board Member, discusses the Institute, its goals, structure, and activities.
INTRADERMAL DELIVERY – Advances in Intradermal Drug Delivery
Zach Marks, MS, RPh, believes efficiency of vaccine use will be critical as the world population continues to grow and vaccine prices continue to rise, and ID administration can help reduce dose cost while potentially improving immunogenicity in traditional and hard-to-treat populations.
SOLID DOSAGE FORMS – Better Treatments Through Innovative Solid Oral Drug Release Technologies
Steven Hamlen, MBA, and Nicholas Johnson, PhD, MBA, discuss recent technology innovations in controlled-release solid oral dose functions and forms as well as more established methods for altering release profiles of molecules, and provide a real-world case study in which applying alternative formulation technology significantly improved an existing therapy and delivered patient and payer benefits.
PACKAGING SOLUTIONS – Overcoming the Challenges of Child-Resistant/Senior-Friendly Closure Development in Today’s Changing World
Steve Stalions and Kurt Attermeier say that as the demand for better CR/SF packaging is on the rise, so too is the market demand for greater cost effectiveness, sustainability, and value-added end-user benefits, and explain how these challenges can be overcome.
ABUSE DETERRENT TECHNOLOGY – New Abuse Deterrent Formulation Technology for Immediate-Release Opioids
Johannes Bartholomäus͛, PhD; Sebastian Schwier, PhD; Martin Brett, et al, review how the INTAC technology platform has been extended to IR formulations with the intention to deter non-oral routes of abuse.
BIOAVAILABILITY ENHANCEMENT – Navigating a Broad Spectrum of Solubilization Technologies: Part II of III
Marshall Crew, PhD, President & CEO, Agere Pharmaceuticals, Inc., continues his multiple-part series discussing today’s most challenging issues in solubility.
ADVANCED DELIVERY DEVICES – The Reconstitution Revolution
Alan Shortall believes with dual-chamber syringes and other emerging device technologies now addressing key market requirements for intuitive reconstitution and injection, the pharmaceutical market for therapies suitable for reconstitution and mixing at the point of delivery is poised for significant rates of growth.
EXECUTIVE INTERVIEW – Ligand: Effective Drug Delivery Solutions With Captisol
Drug Development Executive: Vincent D. Antle, PhD, Senior Director of Technical Operations, and James D. Pipkin, PhD, Senior Director, New Product Development talk about how the company works closely with pharmaceutical and biotechnology companies offering drug delivery solutions that significantly improve stability, solubility, bioavailability, safety, and dosing of APIs.
SPECIAL FEATURE – Hand Held Devices: New Technologies Right the Wrongs of Earlier Devices
Contributor Cindy H. Dubin highlights in this annual report that new devices are coming to market that not only address the trends of home care and a need for delivering larger doses, but are also cleaning up the spotty reputation of early stage devices.
ADVANCED DELIVERY DEVICES – Nanocomposites for Drug Delivery Catheters
Lawrence Acquarulo, PhD, indicates an increased availability of certain medical materials could create a new wave in the development of precision devices to reach smaller areas deeper within the body.
EXCLUSIVE ONLINE CONTENT
Radius Health Announces Commercial Agreement With Paladin Labs
Radius Health, Inc. recently announced it has entered into definitive agreements with Endo Ventures Limited, a subsidiary of Endo International plc to register, commercialize, and distribute abaloparatide on an exclusive basis in….
Vectura Earns $11-Million Milestone as Hikma Receives US FDA Approval for Generic Advair DiskusR
Vectura Group plc recently announced its partner Hikma Pharmaceuticals has launched its generic version of GlaxoSmithKline’s Advair Diskus (fluticasone propionate and salmeterol inhalation powder)….
Gattefossé Continues International Development & Builds Production Site in Texas
Gattefossé is investing 30 million euros in its industrial operations and announced the construction of a brand new manufacturing plant in Lufkin, TX. This asset will produce lipid-based….
New Clinical Trial Data Demonstrates BD Libertas Wearable Injector as a Drug Delivery System
BD (Becton, Dickinson and Company) recently announced publication of the results from a 52-subject human clinical trial with the BD Libertas Wearable Injector…..
Vectura Signs Development Agreement With Kinaset Therapeutics
Vectura Group plc recently announced it has signed a global outlicense and development agreement with Kinaset Therapeutics Inc. for the development and commercialization of….